INDAPTUS THERAPEUTICS INC (INDP) Stock Price, Quote, News and Overview
NASDAQ:INDP - Nasdaq - US45339J1051 - Common Stock - Currency: USD
INDP Quote, Performance and Key Statistics
NASDAQ:INDP (2/21/2025, 8:00:01 PM)
0.8
+0.03 (+3.9%)
The current stock price of INDP is 0.8 USD. In the past month the price decreased by -13.98%. In the past year, price decreased by -56.04%.
INDP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About INDP
Company Profile
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Company Info
INDAPTUS THERAPEUTICS INC
3 Columbus Circle, 15th Floor
New York City NEW YORK US
CEO: Jeffrey A. Meckler
Employees: 7
Company Website: https://indaptusrx.com/
Investor Relations: https://indaptusrx.com/investors/
Phone: 16464272727
INDAPTUS THERAPEUTICS INC / INDP FAQ
What is the stock price of INDAPTUS THERAPEUTICS INC today?
The current stock price of INDP is 0.8 USD. The price increased by 3.9% in the last trading session.
What is the ticker symbol for INDAPTUS THERAPEUTICS INC stock?
The exchange symbol of INDAPTUS THERAPEUTICS INC is INDP and it is listed on the Nasdaq exchange.
On which exchange is INDP stock listed?
INDP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INDAPTUS THERAPEUTICS INC stock?
8 analysts have analysed INDP and the average price target is 8.67 USD. This implies a price increase of 983.75% is expected in the next year compared to the current price of 0.8. Check the INDAPTUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INDAPTUS THERAPEUTICS INC worth?
INDAPTUS THERAPEUTICS INC (INDP) has a market capitalization of 9.61M USD. This makes INDP a Nano Cap stock.
How many employees does INDAPTUS THERAPEUTICS INC have?
INDAPTUS THERAPEUTICS INC (INDP) currently has 7 employees.
What are the support and resistance levels for INDAPTUS THERAPEUTICS INC (INDP) stock?
INDAPTUS THERAPEUTICS INC (INDP) has a resistance level at 0.84. Check the full technical report for a detailed analysis of INDP support and resistance levels.
Should I buy INDAPTUS THERAPEUTICS INC (INDP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INDP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INDP, evaluating the profitability, health, valuation and growth aspects
- INDAPTUS THERAPEUTICS INC (INDP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INDAPTUS THERAPEUTICS INC (INDP) Sales and EPS estimates to see what analysts future expectations are.
- INDAPTUS THERAPEUTICS INC (INDP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INDAPTUS THERAPEUTICS INC (INDP) Insider and Institutional Ownership to learn about the owners and their transactions.
- INDAPTUS THERAPEUTICS INC (INDP) Stock Chart to make your own analysis
- INDAPTUS THERAPEUTICS INC (INDP) Latest news and press-releases to stay up to date.
Does INDAPTUS THERAPEUTICS INC (INDP) stock pay dividends?
INDP does not pay a dividend.
When does INDAPTUS THERAPEUTICS INC (INDP) report earnings?
INDAPTUS THERAPEUTICS INC (INDP) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of INDAPTUS THERAPEUTICS INC (INDP)?
INDAPTUS THERAPEUTICS INC (INDP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
What is the Short Interest ratio of INDAPTUS THERAPEUTICS INC (INDP) stock?
The outstanding short interest for INDAPTUS THERAPEUTICS INC (INDP) is 0.48% of its float. Check the ownership tab for more information on the INDP short interest.
INDP Technical Analysis
INDP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INDP. INDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INDP Financial Highlights
Over the last trailing twelve months INDP reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS increased by 4.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.75% | ||
| ROE | -248.09% | ||
| Debt/Equity | 0 |
INDP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to INDP. The Buy consensus is the average rating of analysts ratings from 8 analysts.